05:17 PM EDT, 05/12/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) reported a Q1 loss Monday of $0.63 per diluted share, widening from the loss of $0.22 a year earlier.

Analysts polled by FactSet expected a loss of $0.75.

As of March 31, the company had cash, cash equivalents and short-term marketable debt securities of $480.1 million.